RE:RE:Competitive cancer drugs -CAR-T issueThanks for further info - I didn't go beyond the headlines as you can tell. Whenever you get involved with a genetic angle, it's that much more risky scientifically. May get FDA to dig a bit deeper with all the programs just in case.
qwerty22 wrote: So my understand is they are trying to bring something new to CAR T, let's say CAR T plus. Take it from bespoke to off-the-shelf so it's probably not a set-back for the whole tech. Allogene were so strongly backed from their inception by Pharma and smart money, have A+ management. Shows you even with the best things go wrong.
Wino115 wrote: See today that the newfangled CAR-T therapies that rely on reengineered cancer T-cells to fight the tumor had a huge stumble. Allogene's program was put on clinical hold because a chromosonal abnormality was discovered in their CAR-T stem cells reimplanted into trial patients.
May slow down that whole angle on using T-Cells for oncology. Stock down 40%. May give pause to using these treatments for tumors. Once again, a more simple to understand, less risky approach of using a receptor with a known chemo bomb may play more heavily in both research and community hospital settings.